ADGRL3 (LPHN3) variants predict substance use disorder.
Arcos-Burgos M, Vélez JI, Martinez AF, Ribasés M, Ramos-Quiroga JA, Sánchez-Mora C, Richarte V, Roncero C, Cormand B, Fernández-Castillo N, Casas M, Lopera F, Pineda DA, Palacio JD, Acosta-López JE, Cervantes-Henriquez ML, Sánchez-Rojas MG, Puentes-Rozo PJ, Molina BSG; MTA Cooperative Group; Boden MT, Wallis D, Lidbury B, Newman S, Easteal S, Swanson J, Patel H, Volkow N, Acosta MT, Castellanos FX, de Leon J, Mastronardi CA, Muenke M.
Arcos-Burgos M, et al.
Transl Psychiatry. 2019 Jan 29;9(1):42. doi: 10.1038/s41398-019-0396-7.
Transl Psychiatry. 2019.
PMID: 30696812
Free PMC article.